40 news items
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
AZN
MRK
MRNA
8 May 24
is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval regulations based on the objective response rate (ORR
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
MRK
8 May 24
and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
ABBV
ATNM
AZN
8 May 24
, primed for M&A interest."
Market Response and Growth Prospects
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA
CTMX
MRK
7 May 24
cancer types. IFNα2b provides a potentially superior approach to activating anti-tumor immune responses compared to other cytokines. CX-801
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
. Ligand is not responsible for, and has no role in, the development of such products or programs.
Ligand
qpr3ei
IBRX
MRK
3 May 24
for patients with non-muscle invasive bladder cancer since 1977.
BCG is a benign bacterium that induces an immune response in the bladder
37a soesyxsma
MRK
1 May 24
is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval regulations based on the objective response rate (ORR
lxezreecypx
MRK
29 Apr 24
:
V116 elicited immune responses that were noninferior compared to PPSV23 for the 12 serotypes
d0q r145hqk9l
MRK
25 Apr 24
the serotypes responsible for approximately 83% of invasive pneumococcal disease in adults 65 and older. Merck also announced plans to initiate clinical
jn6j2dn 9m9p6kxxmyq4gs5
IMMP
MRK
24 Apr 24
HNSCC) with negative PD-L1 expression.
The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9
70os8o5snd
MRK
19 Apr 24
survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to placebo in combination with chemotherapy in the intention
tve 9vvq5l4
MRK
18 Apr 24
their response to recent developments related to Merck & Co. This information provides a snapshot of how analysts perceive the current state
8l7l3b67lbu t2
ADMA
ANIP
MRK
11 Apr 24
from the study showed that treatment with the combination not only achieved positive clinical responses in HPV- HNSCC patients but even showed
0g1lnt6nlhfzj90ijbru5d08s8d5rtxmy7wybvalcb
MRK
PCVX
PFE
10 Apr 24
, leading to a stronger immune response.
Vaxcyte also has a 31-valent vaccine. Regarding Merck’s V116, Vaxcyte predicts its
poc14j8ep2xrz6b pujhv
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
cat0i17asisd7ral2 l4r6
MRK
MRNA
9 Apr 24
patients in patients with a type of head and neck cancer, the vaccine showed a positive response.
mRNA-4157 + pembrolizumab was associated
1gcwdg4q
MRK
4 Apr 24
, and key secondary endpoints include objective response rate and duration of response.
f35r0ekb7ybi468b1wamq3pfsp9cwoauhmsop5jvlh2ld7thtrbz
MRK
4 Apr 24
survival and overall survival, and key secondary endpoints include objective response rate and duration of response
lj885yh 7l199pfz39au
MRK
1 Apr 24
, it signifies their response to recent developments related to Merck & Co. This offers insight into analysts' perspectives on the current state
jtlc2tplsbdyxc83imwhznvf5kbtwfcj1dhkzgqhiyvhvjkcqqvmh2 5fob
MRK
28 Mar 24
secondary endpoints include pathologic complete response (pCR) and major pathological response (mPR). The study enrolled 797 patients who were randomly